Patheon N.V. continues its investment in facilities, having signed an agreement to acquire an active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina, from Roche Holdings, Inc.
According to Patheon, the global provider of drug development and delivery solutions will acquire the site for an “immaterial” sum, plus the cost of inventory and spare parts. It has also entered into a multi-year supply arrangement with Roche that is expected to cover the costs associated with running the site.
“The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” said James Mullen, CEO of Patheon.
With the addition of this 300,000 square-foot facility, the company expands its capacity for manufacturing highly potent compounds, and adds capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying. The site hold reactors ranging from 50-11,000 liters producing multiple products simultaneously, fully compliant with all applicable regulations. It will provide Patheon with a major U.S. API operation, and with the importance of manufacturing costs critical to biosimilars’ success, this new site may prove to be a major asset.
Read the full press release